A. Abad

发表

Cytotoxic Effects of Topotecan Combined with Various Active G2/M-Phase Anticancer Drugs in Human Tumor-Derived Cell Lines

M. Taron, C. Plasencia, A. Abad, 2000, Investigational New Drugs.

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.

M. Ychou, A. Abad, M. Marty, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors

R. Salazar, James C Yao, A. Abad, 2011, Cancer and Metastasis Reviews.

A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers.

E. Felip, R. Rosell, M. Monzó, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer.

R. Rosell, M. Monzó, A. Abad, 1998, Gastroenterology.

Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer

R. Rosell, A. Abad, M. Margelí, 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.

J. Tabernero, A. Abad, B. Massuti, 2012, The oncologist.

Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.

A. Carrato, J. Tabernero, A. Abad, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

UFT in Elderly Patients with Colorectal Cancer

A. Abad, J. Manzano, 2003 .

Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan.

A. Abad, B. Cirauqui, E. Martínez-Balibrea, 2007, Oncology reports.

Guides for adjuvant treatment of colon cancer

A. Carrato, A. Abad, A. Cervantes, 2006 .

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

A. Carrato, V. Moreno, A. Abad, 2010, British Journal of Cancer.

Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors

A. Carrato, A. Abad, B. Massuti, 2004, Anti-cancer drugs.

Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer.

G. Scagliotti, R. Rosell, M. Taron, 2002, Pharmacogenomics.

UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors

A. Carrato, A. Abad, E. Díaz-Rubio, 2006, Anti-cancer drugs.

A preliminary report of a phase II trial. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Spanish Group for the Treatment of Gastrointestinal Tumors (TTd Group).

A. Abad, E. Díaz-Rubio, M. Navarro, 1997, Oncology.

Resectability of liver metastases (LM) in patients with advanced colorectal cancer (ACRA) after treatment with the combination of oxaliplatin (OXA), irinotecan (IRI) and 5FU. Final results of a phase II study

A. Carrato, J. Tabernero, A. Abad, 2005 .

Reflections on adjuvant treatment of gastric cancer

A. Abad, J. Manzano, C. Martí, 2007, Therapeutics and clinical risk management.

Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

J. Tabernero, A. Abad, B. Massuti, 2012, The oncologist.

Molecular staging of non-small cell lung cancer according to K-ras genotypes.

A. Ariza, R. Rosell, M. Monzó, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

A. Carrato, R. Salazar, C. García-Girón, 2021, Drugs & Aging.

Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials

A. Carrato, A. Abad, B. Massuti, 2019, ESMO Open.

Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).

A. Carrato, A. Abad, C. Montagut, 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin‐based chemotherapy

N. Neamati, E. Musulen, C. Plasencia, 2009, International journal of cancer.

Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.

A. Carrato, A. Abad, A. Antón, 2003, Methods and findings in experimental and clinical pharmacology.

Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial

A. Carrato, R. Salazar, A. Abad, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease: The PLANET study.

A. Carrato, A. Abad, B. Massuti, 2014 .

Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.

E. Guinó, A. Abad, J. Aparicio, 2008, European journal of cancer.

Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.

A. Abad, B. Massuti, F. Rivera, 2013, Clinical colorectal cancer.

A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site.

J. Mate, C. Balañà, R. Rosell, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Biweekly irinotecan (CPT-11) plus 5-FU as first-line chemotherapy for elderly patients with metastatic colorectal cancer (MCRC). Final results of the Spanish Digestive Group (TTD) study.

A. Abad, A. Antón, E. Díaz-Rubio, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.

R. Rosell, M. Taron, A. Abad, 2002, Lung cancer.

Antiproliferative effects of ZD0473 (AMD473) in combination with 5-Fluorouracil or SN38 in human colorectal cancer cell lines

M. Taron, C. Plasencia, A. Abad, 2004, Investigational New Drugs.

Randomized phase III trial of the TTD Group comparing capecitabine and oxaliplatin (XELOX) vs. oxaliplatin and 5-fluorouracil in continuous infusion (FUFOX) as first line treatment in advanced or metastatic colorectal cancer (CRC).

A. Carrato, J. Tabernero, A. Abad, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer

J. Carles, R. Rosell, A. Abad, 1992, Investigational New Drugs.

M. Esteller, A. Abad, V. Ruiz de Porras, 2015, Molecular Cancer Therapeutics.

K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma.

A. Ariza, R. Rosell, M. Monzó, 1994, Lung cancer.

Inestabilidad de microsatélites y cáncer colorrectal

C. Plasencia, A. Abad, 2005 .

Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer

R. Rosell, M. Monzó, A. Abad, 2001, Diseases of the colon and rectum.

Microsatellite alterations at 5q21, 11p13, and 11p15.5 do not predict survival in non-small cell lung cancer.

R. Rosell, M. Monzó, A. Abad, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Platelet Count and Survival in Patients with Colorectal Cancer – a Preliminary Study

A. Abad, M. Monreal, J. Fernández-Llamazares, 1998, Thrombosis and Haemostasis.

Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway

A. Abad, L. Howells, L. Sumoy, 2016, Scientific Reports.

PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines

E. Musulen, Cristina Guardia, A. Abad, 2015, PloS one.

A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines

N. Neamati, E. Musulen, C. Plasencia, 2009, Molecular Cancer Therapeutics.

Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer

E. Bandrés, J. García-Foncillas, M. Taron, 2009, Molecular Cancer Therapeutics.

Chromosomal imbalance maps of human 5FU-resistant colorectal cancer cell lines: implications in the analysis of 5FU-acquired resistance mechanisms.

H. McLeod, M. Taron, C. Plasencia, 2003, International journal of oncology.

Treatment recommendations for metastatic colorectal cancer

A. Carrato, J. Tabernero, J. García-Foncillas, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism

R. Rosell, M. Taron, A. Abad, 2003, Investigational New Drugs.

A phase II study of days 1 and 8 cisplatin and recombinant alpha‐2B interferon in advanced non‐small cell lung cancer

J. Carles, A. Ariza, R. Rosell, 1991, Cancer.

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

A. Carrato, J. Tabernero, J. García-Foncillas, 2012, PloS one.

Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial.

J. Padilla, R. Rosell, A. Abad, 1999, Lung cancer.

Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells.

N. Neamati, C. Plasencia, A. Abad, 2006, International journal of oncology.

Guidelines for the detection and treatment of liver metastases of colorectal cancer

A. Carrato, J. Figueras, A. Abad, 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Randomized, double-blind cross-over study of acute cisplatin-induced nausea and vomiting, comparing a new schedule of the combination of metoclopramide and methylprednisolone versus metoclopramide alone.

A. Abad, E. Díaz-Rubio, M. Martín, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

5-Fluorouracil, folinic acid, epidoxorubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer. A phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).

A. Tres, A. Abad, C. Camps, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Consensus on the treatment of pancreatic cancer in Spain

M. Hidalgo, J. Tabernero, A. Abad, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients.

J. Carles, R. Rosell, A. Abad, 1992, European journal of cancer.

TTD consensus document on the diagnosis and management of exocrine pancreatic cancer

A. Carrato, J. Tabernero, J. García-Foncillas, 2014, Clinical and Translational Oncology.

Anti-Cancer Drugs 2008 Author Index to Volume 19.

E. Azizi, A. Abad, P. Bacchini, 2008, Anti-cancer drugs.

Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer.

J. Carles, A. Ariza, R. Rosell, 1993, Lung cancer.

Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer

M. Esteller, R. Salazar, Cristina Santos, 2013, Journal of the National Cancer Institute.

Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer

R. Rosell, A. Abad, N. Ribelles, 1992, Investigational New Drugs.

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).

A. Carrato, A. Abad, B. Massuti, 2017, European journal of cancer.

Upper Extremity Deep Venous Thrombosis in Cancer Patients with Venous Access Devices - Prophylaxis with a Low Molecular Weight Heparin (Fragmin)

R. Rosell, A. Abad, M. Monreal, 1996, Thrombosis and Haemostasis.

Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study.

A. Carrato, J. Tabernero, A. Abad, 2009, Critical reviews in oncology/hematology.

Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

A. Carrato, A. Abad, J. Maurel, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer

A. Carrato, A. Abad, M. Guillot, 2000, Revista de Oncología.

UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients.

A. Carrato, A. Abad, A. Antón, 1999, Oncology.

Tumour site, sex, and survival in colorectal cancer

R. Rosell, A. Abad, 2000, The Lancet.

UFT Plus Oral Folinic Acid as Therapy for Metastatic Colorectal Cancer in Older Patients

A. Abad, Cristina Martín, E. Díaz-Rubio, 1997 .

Sequential Combination of Methotrexate (MTX), 5‐Fluorouracil (FU), and High‐Dose Folinic Acid (FA) in Advanced Colorectal Cancer: Double Biochemical Modulation?

J. Carles, R. Rosell, A. Abad, 1991, American journal of clinical oncology.

Sequential methotrexate, 5‐fluorouracil (5‐FU), and high dose leucovorin versus 5‐FU and high dose leucovorin versus 5‐FU alone for advanced colorectal cancer. A multi‐institutional randomized trial

R. Rosell, A. Abad, A. Font, 1995, Cancer.

Abstract 5478: Curcumin mediates reversion to oxaliplatin-acquired resistance in colorectal cancer cell lines through modulation of nuclear factor κB (NFκB) and cyclin-dependent kinase 5 (CDK5)

A. Abad, E. Martínez-Balibrea, A. Martínez-Cardús, 2015 .

Epirubicin plus a calmodulin inhibitor (trifluoperazine) activity in advanced pancreatic adenocarcinoma. T.T.D. Cooperative Spanish Group.

C. Balañà, A. Abad, A. Font, 1994, European Journal of Cancer.

5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors.

J. Carles, R. Rosell, A. Abad, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer.

A. Carrato, A. Abad, A. Antón, 2005, Clinical colorectal cancer.

Pharmacogenomic research and serum DNA analysis in the treatment of non-small cell lung cancer

J. Jassem, R. Rosell, M. Monzó, 2001, Revista de Oncología.

Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer.

A. Carrato, A. Abad, L. Pronk, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

New drugs in the treatment of gastric tumors

A. Abad, 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study

A. Carrato, J. Tabernero, A. Abad, 2008, Acta oncologica.

Abstract 2610: TYMS and XRCC1 gene polymorphisms as possible predictors for the addition of oxaliplatin to 5FU in the adjuvant treatment of stage II and III colorectal cancer

R. Salazar, A. Abad, F. Rivera, 2010 .

A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

J. Mate, A. Ariza, R. Rosell, 1994, The New England journal of medicine.

Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801).

R. Salazar, A. Abad, I. Durán, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant chemotherapy in stage Illa non-small cell lung cancer LEARNING POINTS *

R. Komaki, E. Atkinson, A. Ariza, 2022 .

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.

J. Tabernero, A. Abad, F. Rivera, 2012, The oncologist.

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).

A. Carrato, A. Abad, M. Valladares-Ayerbes, 2017, European journal of cancer.

A. Carrato, J. Tabernero, A. Abad, 2009, Critical reviews in oncology/hematology.